Cancer Genetics completes cut-price IPO
This article was originally published in Clinica
Executive Summary
Cancer Genetics has finally gone public – but the $6.9 million raised has fallen well short of what it had originally been looking for. The personalised medicine firm sold six million shares at $10 each, plus an over-allotment allocation of 90,000 shares.